
Suven Life Sciences Share Price Target 2026: Stock Analysis, Share Price Today, Bull Case and Bear Case After Q1 FY27
Updated: 8 Oct 2026 • 9:48 am
Posted by:

Suven Life Sciences Rs 305.55 (7 Oct 2026 close). 52-week range Rs 124.11 to Rs 403.35. Q1 FY27 consolidated loss Rs 127.61 cr; masupirdine Phase 3 about 95% enrolled.
Quick Answer
The Suven Life Sciences share price target for 2026 is Rs 240 to Rs 312, which is between 22 percent below and 2 percent above the last close of Rs 305.55, with bull and bear cases of Rs 360 to Rs 456 and Rs 144 to Rs 192. Suven Life Sciences reported a Q1 FY27 consolidated net loss of Rs 127.61 crore against Rs 51.52 crore a year ago as R&D spending rose, with its US arm contributing a Rs 111.49 crore loss. The lead drug masupirdine for agitation in Alzheimer's dementia is in Phase 3 with about 95 percent enrolment, the company has Rs 857.64 crore of warrant funding, and the stock is up 146 percent from its March low but down 26 percent from its high. No brokerage price target was available on the sources we track as of 7 October 2026, so every range below is a Univest research scenario.
The Suven Life Sciences share price target for 2026 is Rs 240 to Rs 312 in the Univest base case, with the stock at Rs 305.55 at the 7 October 2026 close. That is 24.2 percent below its 52-week high of Rs 403.35 and 146.2 percent above its 52-week low of Rs 124.11, and the stock moved up 45.9 percent over the past year. Suven Life Sciences is a Hyderabad-based clinical-stage biopharma company developing drugs for central nervous system disorders, with five clinical assets. Debt to equity is 0.03 and the company pays no dividend.
Three things changed since the last update: Q1 FY27 results on 6 August showed a wider loss on higher R&D, the stock rose 5.5 percent after results, and it fell five weeks in a row from Rs 355 to Rs 297 after a Rs 403 high. This Suven Life Sciences stock analysis covers the Suven Life Sciences share price today, the Suven Life Sciences share price target for 2026, 2027 and 2030, the Q1 FY27 numbers, catalysts and risks, key price levels and a Suven Life Sciences buy or sell view.
Click Here – Get Free Investment Predictions
What Is the Suven Life Sciences Share Price Target for 2026?
The 2026 target for Suven Life Sciences shares is Rs 240 to Rs 312 in the Univest base case, which is -21.5% to +2.1% against the last close. The bull case is Rs 360 to Rs 456 and the bear case is Rs 144 to Rs 192. No brokerage price target was available on the sources we track as of 7 October 2026, so every range below is a Univest research scenario. Analyst consensus is used as a cross-check, not as the base.
Suven Life Sciences Share Price Target Scenarios: Bull Case, Base Case and Bear Case
| Scenario | FY28E Book Value | Target Multiple | Price Target (Rs) | Move vs Rs 305.55 |
|---|---|---|---|---|
| Bull Case | Rs 24 | 15x to 19x | 360 to 456 | +17.8% to +49.2% |
| Base Case | Rs 24 | 10x to 13x | 240 to 312 | -21.5% to +2.1% |
| Bear Case | Rs 24 | 6x to 8x | 144 to 192 | -52.9% to -37.2% |
Suven has no earnings, so a PE valuation does not apply. The ranges use price to book on a FY28 book value of Rs 24 per share, which compares with Rs 24.23 now. The stock trades at 12.6 times book, and the cases range from a de-rating to 6 to 8 times book if the trial disappoints to a re-rating to 15 to 19 times if it succeeds. The PE multiple does not apply because earnings are negative, so the table uses price to book in place of an EPS estimate, and the book value is a Univest assumption, not company guidance. Those assumptions set the Suven Life Sciences share price target range around the current price.
Suven Life Sciences Company Overview and Share Price Today as of 7 October 2026
Suven Life Sciences share price today is Rs 305.55 on the NSE at the 7 October 2026 close, before the market opens on 8 October. The market capitalisation is Rs 8,639 crore, and the stock has no PE because earnings are negative, against an industry average of 62.7 times. The Univest base case Suven Life Sciences share price target of Rs 240 to Rs 312 is -21.5% to +2.1% from here. The table below sets out the key numbers behind the Suven Life Sciences share price target.
| Parameter | Value | Context |
|---|---|---|
| NSE Ticker | SUVEN | BSE code 530239 |
| Sector | Clinical-stage CNS biopharma | Per Univest sector classification |
| Last Close (NSE) | Rs 305.55 | 7 Oct 2026 close |
| 52-Week High | Rs 403.35 | CMP is 24.2% below |
| 52-Week Low | Rs 124.11 | CMP is 146.2% above |
| 1-Year Return | About +46% | Weekly close Rs 209.41 on 10 Oct 2025 to Rs 305.55 |
| Market Capitalisation | Rs 8,639 crore | Small cap clinical-stage biopharma |
| Trailing P/E | Not applicable (loss) | Industry P/E about 62.71x |
| P/B Ratio | About 12.62x | Book value Rs 24.23 per share |
| EPS (TTM) | Rs -12.47 | Trailing twelve months |
| Return on Equity | About -46.7% | Debt to equity 0.03 |
| Dividend Yield | Nil | No dividend |
| 12-Month Target (Base Case) | Rs 240 to Rs 312 | Univest base case |
| Bull Case | Rs 360 to Rs 456 | +17.8% to +49.2% |
| Bear Case | Rs 144 to Rs 192 | -52.9% to -37.2% |
Track live price, fundamentals and results for Suven Life Sciences on the Univest Screener.
How Did Suven Life Sciences Perform in Q1 FY27?
Suven Life Sciences reported a Q1 FY27 consolidated net loss of Rs 127.61 crore against Rs 51.52 crore a year ago, and a standalone net loss of Rs 16.12 crore against Rs 14.78 crore. Operating revenue is small and other income funds part of the cost. Together these Q1 FY27 numbers anchor the Suven Life Sciences share price target.
| Metric | Q1 FY27 | Context |
|---|---|---|
| Consolidated Net Loss | Rs 127.61 crore | Against Rs 51.52 crore a year ago |
| Standalone Net Loss | Rs 16.12 crore | Against Rs 14.78 crore |
| US Subsidiary Loss | Rs 111.49 crore | Suven Neurosciences Inc |
| Q4 FY26 Loss | Rs 45.60 crore | Consolidated |
| Warrant Funding | Rs 857.64 crore | 6.4 crore warrants at Rs 134 |
| Phase 3 Enrolment | About 95% | Masupirdine; Alzheimer's agitation |
The wider loss reflects a sharp rise in R&D spending on the Phase 3 programme, driven by the US subsidiary. The monitoring agency reported no deviation in the use of the Rs 857.64 crore warrant proceeds, and the company has formed a Singapore subsidiary for global ventures. The FY27 outlook from management is the main input for these estimates. These numbers sit behind every range in the scenario table above, so they anchor the Suven Life Sciences share price target.
Why Is Suven Life Sciences Share Price Up 146 Percent From Its March Low?
Suven Life Sciences shares are about 146 percent above the Rs 124.11 low of the week of 23 March 2026 and up 46 percent in a year. The stock jumped 21 percent in the week of 30 March and 24 percent in the week of 6 April, and rose 25.7 percent in the week of 18 May on 3.85 crore shares, with no confirmed cause for the May move.
It added 22.6 percent in the week of 29 June, set an all-time high near Rs 403.35 in the week of 31 August and then fell five weeks in a row to Rs 297. The shares are 26 percent below the high at Rs 305.55 as investors wait for the Phase 3 readout. The Suven Life Sciences share price target scenarios below account for that move.
Key Catalysts for the Suven Life Sciences Share Price Target in 2026
4 catalysts matter most for the Suven Life Sciences share price target, and sector tailwinds in Clinical-stage CNS biopharma are part of the case. Together they decide whether the base case is reached.
1. Phase 3 Trial
Masupirdine is in Phase 3 for agitation in Alzheimer's dementia with about 95 percent enrolment. A positive readout would re-rate the stock. If it plays out, the Suven Life Sciences share price target moves toward the top of the base range.
2. Funded Runway
The company raised Rs 857.64 crore through warrants and the monitoring agency found no deviation. Funding supports the trial. Strength here would support the upper end of the Suven Life Sciences share price target.
3. Pipeline Breadth
Five clinical assets target narcolepsy, depression and cognition as well. A second success would diversify risk. Delivery on this point keeps the Suven Life Sciences share price target on track.
4. Promoter Holding
Promoters hold about 65.5 percent. High holding shows commitment. Better news here would lift the Suven Life Sciences share price target toward the bull case.
What Are the Key Risks to the Suven Life Sciences Share Price Target?
The main risks are a trial failure, cash burn, dilution and a rich book multiple. Each can pull the Suven Life Sciences share price target lower.
Trial Failure
Phase 3 results are binary. A failed or delayed readout would cut the stock sharply. If it materialises, the Suven Life Sciences share price target would slip toward the bear case.
Cash Burn
The consolidated loss was Rs 127.61 crore in one quarter. Higher R&D shortens the runway. This is the main downside risk to the Suven Life Sciences share price target.
Dilution
The company has issued warrants and a rights entitlement line is listed. More equity would dilute holders. A worsening here would cut the Suven Life Sciences share price target toward the low end of the range.
Book Multiple Reset
The stock trades at 12.6 times book. A bear case of Rs 24 book value at 6 times would put the price near Rs 144. Watch it closely, because it can pull the Suven Life Sciences share price target lower quickly.
Suven Life Sciences Stock Analysis: Support and Resistance Levels for the Share Price Target
Suven Life Sciences stock analysis on weekly charts shows a range of Rs 297 to Rs 364 since mid-September, with the stock near the lower end.
The first support level is Rs 297.20 to Rs 301.10, the lows of the weeks of 5 and 28 September. Below that, Rs 124.11 is the 52-week low and there is no weekly support in between.
The first resistance level is Rs 316.90 to Rs 336, the highs of the weeks of 5 and 28 September. Above that, Rs 345.20 to Rs 363.95 marks the highs of the weeks of 21 and 14 September. These levels come from weekly price action, are not trade recommendations, and frame the near-term Suven Life Sciences share price target.
Suven Life Sciences Share Price Target 2026, 2027 and 2030: Short, Medium and Long Term
Short-Term Suven Life Sciences Share Price Target (3 to 6 Months)
In the near term the stock is likely to trade between Rs 297 and Rs 336. A close above Rs 336 would put Rs 345 to Rs 364 in play, while a weekly close under Rs 297 would open a slide toward Rs 250. Trial news is the main trigger. This range anchors the near-term Suven Life Sciences share price target.
12-Month and 2027 Suven Life Sciences Share Price Target
The 12-month target price is Rs 240 to Rs 312, valued on 10 to 13 times FY28 book value of Rs 24. The range across scenarios runs from Rs 144 in the bear case to Rs 456 in the bull case.
Long-Term Suven Life Sciences Share Price Target for FY29 to 2030
For FY29 to 2030 the Univest scenario range is Rs 192 to Rs 336. This assumes book value of Rs 24 in FY29 and Rs 24 in FY30 and a multiple of 8 to 14 times. It needs the Alzheimer's agitation Phase 3 trial to read out well, funding to last through the trials and no major dilution. This is the long-term Suven Life Sciences share price target in the Univest scenarios.
Bull Case and Bear Case for Suven Life Sciences Share Price Target
Bull Case Rs 360 to Rs 456
The bull case of Rs 360 to Rs 456 for the Suven Life Sciences share price target needs book value of Rs 24 and the market to pay 15 to 19 times for it. It is +17.8% to +49.2% from the last close.
Bear Case Rs 144 to Rs 192
The bear case of Rs 144 to Rs 192 for the Suven Life Sciences share price target equals 6 to 8 times FY28 book value of Rs 24 and sits above the Rs 124.11 low. It is -52.9% to -37.2% from the last close.
Is Suven Life Sciences a Good Buy at Rs 306? Suven Life Sciences Buy or Sell View
Whether Suven Life Sciences is a buy at Rs 305.55 depends on horizon and risk appetite. The base case sits between 22 percent below and 2 percent above the current price, the stock is 26 percent below its high, and the open question is the Phase 3 readout. The Suven Life Sciences share price target range is the starting point for that decision.
Long-term holders may focus on the trial, cash runway and dilution, and treat Rs 297 as the level to watch. Short-term traders may prefer to wait for a close above Rs 336. Check institutional holding in the September quarter filing for signs of accumulation or selling. Consult a SEBI-registered advisor before acting, since this Suven Life Sciences buy or sell view is educational.
How to Invest in Suven Life Sciences Shares
Step 1: Check the live price, valuation and the latest Suven Life Sciences share price target range on the Univest Screener.
Step 2: Open a demat and trading account with a SEBI-registered broker such as Univest before acting on any Suven Life Sciences share price target.
Step 3: Search for SUVEN on the NSE or 530239 on the BSE in your trading app.
Step 4: Place a limit order near your planned entry and size the position so a fall to Rs 144 is bearable.
Step 5: Track trial updates, cash burn and Q2 FY27 results and set price alerts on the Univest App to follow any change in the Suven Life Sciences share price target.
Conclusion
Suven Life Sciences closed at Rs 305.55 against a Univest base case share price target of Rs 240 to Rs 312, a bull case of Rs 360 to Rs 456 and a bear case of Rs 144 to Rs 192. Q1 FY27 showed a Rs 127.61 crore consolidated loss as R&D rose, with the Alzheimer's agitation Phase 3 trial near full enrolment. The main risks are a trial failure, cash burn and dilution.
The stock is 24.2 percent below its 52-week high, so the base case sits between 22 percent below and 2 percent above the current price. The triggers to watch are trial updates, cash burn and Q2 FY27 results and the Rs 297 and Rs 336 levels. Re-check the Suven Life Sciences share price target after each quarterly result. Investors with a long horizon and tolerance for volatility can track these triggers, while others may prefer to size positions carefully.
Download the Univest iOS App or Univest Android App to track Suven Life Sciences live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Suven Life Sciences Share Price Target 2026
What is the Suven Life Sciences share price target for 2026?
Ans. The Suven Life Sciences share price target for 2026 is Rs 240 to Rs 312 in the Univest base case, with a bull case of Rs 360 to Rs 456 and a bear case of Rs 144 to Rs 192. No brokerage target was available on the sources we track as of 7 October 2026, so these are Univest research scenarios. These are estimates and can change after the Q2 FY27 results.
What is the Suven Life Sciences share price target for 2027?
Ans. The Suven Life Sciences share price target for 2027 is Rs 240 to Rs 312 in the base case, valued on 10 to 13 times FY28 book value of Rs 24. The scenario range runs from Rs 144 to Rs 456.
Is Suven Life Sciences a good buy at Rs 305.55?
Ans. Whether Suven Life Sciences is a good buy at Rs 305.55 depends on your horizon, risk appetite and how you read the Suven Life Sciences share price target. The pipeline has upside if the Phase 3 trial succeeds, but the company is pre-revenue, loses money and the stock is highly speculative. Consult a SEBI-registered advisor before investing.
What are the key risks to the Suven Life Sciences share price target?
Ans. The key risks to the Suven Life Sciences share price target are trial failure, cash burn, dilution and book multiple reset. Phase 3 results are binary. A failed or delayed readout would cut the stock sharply.
What are the key catalysts for the Suven Life Sciences share price target?
Ans. The key catalysts for the Suven Life Sciences share price target are phase 3 trial, funded runway, pipeline breadth and promoter holding. Masupirdine is in Phase 3 for agitation in Alzheimer's dementia with about 95 percent enrolment. A positive readout would re-rate the stock.
Where can I track Suven Life Sciences share price today and Suven Life Sciences share price target updates?
Ans. You can track the live Suven Life Sciences share price, results and any change to the Suven Life Sciences share price target on the Univest Screener and the Univest App. Download the Univest iOS App or Univest Android App for research from SEBI-registered analysts.
What are Suven Life Sciences's 52-week high and low?
Ans. Suven Life Sciences's 52-week high is Rs 403.35 and its 52-week low is Rs 124.11, based on weekly NSE data. At Rs 305.55 the stock is 24.2 percent below the high and 146.2 percent above the low. Both levels frame the Suven Life Sciences share price target.
How to buy Suven Life Sciences shares?
Ans. Open a demat account with a SEBI-registered broker such as Univest, search for SUVEN on the NSE or 530239 on the BSE, and place a limit order near your entry price, using the Suven Life Sciences share price target range as a guide. Size the position so a fall to Rs 144 is bearable, and check the live price on the Univest Screener first.
Recent Articles

Stocks to Buy for 2027: Ventura's Samvat 2083 Picks Include HDFC Bank, Paytm, Meesho, Ather, LG Electronics India and Park Medi World, With Targets Up to 75% Above the Price at Publication
13 November 2026

Microsoft Outage on 13 November 2026 Sends Traders Back to Phones and Fax: What the Outlook, Teams and Copilot Failure Means for Global Markets, Indian Brokerages and Investors
13 November 2026

Ingersoll Rand Dividend of Rs 20 Per Share: Record Date 19 November 2026, Payout on 2 December and What the Q2 FY27 Profit Rise of 9% Says About the Payout and the Stock
13 November 2026

Viceroy Hotels Share Price Gains Nearly 4% After Q2 FY27 Results: Revenue Up 56.5% to Rs 48.20 Crore but Profit Halves to Rs 2.23 Crore, and Why the Rs 106 Crore Rights Issue Matters on 13 November 2026
13 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Stocks to Buy for 2027: Ventura's Samvat 2083 Picks Include HDFC Bank, Paytm, Meesho, Ather, LG Electronics India and Park Medi World, With Targets Up to 75% Above the Price at Publication
Microsoft Outage on 13 November 2026 Sends Traders Back to Phones and Fax: What the Outlook, Teams and Copilot Failure Means for Global Markets, Indian Brokerages and Investors
Ingersoll Rand Dividend of Rs 20 Per Share: Record Date 19 November 2026, Payout on 2 December and What the Q2 FY27 Profit Rise of 9% Says About the Payout and the Stock
Viceroy Hotels Share Price Gains Nearly 4% After Q2 FY27 Results: Revenue Up 56.5% to Rs 48.20 Crore but Profit Halves to Rs 2.23 Crore, and Why the Rs 106 Crore Rights Issue Matters on 13 November 2026
SC Agrotech Bonus Issue and Stock Split: 4:5 Bonus and 1:10 Split Proposed as the Stock Locks a 5% Upper Circuit at Rs 62.38, Q2 Profit Up 48 Times and What Shareholders Should Check Before the 11 December EGM

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





